Pacific Edge (ASX: PEB) — Perfil da empresa, notícias e dados financeiros
Pacific Edge is a global cancer diagnostics company that develops and commercializes non-invasive genomic biomarker tests for the early detection and ongoing management of bladder cancer.
Pacific Edge
Pacific Edge is a global cancer diagnostics company that develops and commercializes non-invasive genomic biomarker tests for the early detection and ongoing management of bladder cancer. Headquartered in New Zealand, the company operates specialized laboratories in Dunedin, New Zealand, and Hershey, Pennsylvania, to serve healthcare providers globally. Its urine-based molecular diagnostic suite assists clinicians in evaluating patients presenting with hematuria and monitoring individuals for recurrent urothelial carcinoma. By integrating gene expression profiling into clinical workflows, the business provides objective diagnostic tools that aid in ruling out malignancy, reducing reliance on unnecessary invasive procedures, and improving patient care standards across international healthcare markets.
Resumo
Operações
Produtos e/ou serviços de Pacific Edge
- Hematuria Triage Diagnostics: Non-invasive urine gene expression tests designed to rule out urothelial carcinoma in patients presenting with micro- or gross hematuria, helping clinicians reduce unnecessary invasive cystoscopy procedures and streamline initial clinical evaluation workflows.
- Bladder Cancer Diagnostic Aids: Targeted genomic biomarker tests used as diagnostic adjuncts for patients undergoing investigation for suspected bladder cancer, helping clinicians identify tumor presence through urine sample analysis in conjunction with standard clinical evaluations.
- Recurrence Surveillance Testing: Non-invasive molecular diagnostic assays tailored for the ongoing surveillance of patients previously treated for bladder cancer, monitoring tumor recurrence through routine urine sampling and reducing the frequency of follow-up invasive diagnostic procedures.
- Advanced Diagnostic Resolution: Specialized gene expression profiling assays optimized to evaluate complex clinical presentations and assist in identifying high-grade or aggressive bladder cancer cases where standard diagnostic results remain inconclusive.
- Clinical Laboratory Services: Operation of certified centralized testing facilities in Dunedin, New Zealand, and Hershey, Pennsylvania, providing molecular processing of urine specimens under ISO 15189, CLIA, CAP, and New York State regulatory accreditations.
- Clinical Research and Evidence Generation: Execution of international prospective clinical trials and utility studies to validate genomic test performance, support inclusion in clinical practice guidelines, and secure reimbursement coverage across public and private health insurance systems.
equipe executiva do Pacific Edge
- Peter MeintjesChief Executive Officer
- Grant GibsonChief Financial Officer
- Darrell MorganChief Operating Officer
- Justin HarveyChief Technology Officer
- Parry GuilfordChief Scientific Officer & Member of Scientific Advisory Board
- Zoe O'DonnellGlobal Head of People & Culture
- Glen CostinPresident of Asia Pacific
- Tamer AboushwarebChief Medical Officer
- James J. VaughnChief Commercial Officer
- Willy IglesiasChief Digital Officer
Últimas notícias sobre a Pacific Edge
Pacific Edge advances US commercial recovery progress
AustraliaPacific Edge advances APAC business towards profitability
AustraliaPacific Edge finalises NZ$36.1M capital raising
AustraliaPacific Edge eyes profitability after US Medicare breakthrough
AustraliaPacific Edge secures vital Medicare draft coverage
AustraliaPacific Edge raises NZ$25.4M in upsized placement
Australia
Comunicados recentes
O que a Pacific Edge (PEB) comunicou ao mercado, do mais recente para o mais antigo.
- Change in substantial holding
- NZX - Capital Change Notice - Expiry of Options
- NZX - Capital Change Notice - Exercise of Options
- Notification of cessation of securities - PEB
- Application for quotation of securities - PEB
Histórico de dividendos
Dividendos por ação pagos pela Pacific Edge, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2027(até o momento) | — | — | — | $0.0200 |
| FY2026 | — | — | — | $0.0400 |
| FY2025 | — | — | — | $0.0400 |
| FY2024 | — | — | — | $0.0400 |
| FY2023 | — | — | — | $0.0400 |
Principais indicadores financeiros
Resultados divulgados pela Pacific Edge, em NZD.
- Cap. de mercado
- 236 mi
- Receita (TTM)
- 13 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.0
- Dividend yield
- —
- Margem de lucro
- -275.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 11,6 mi | -38,1 mi | -36 mi | |
| 21,8 mi | -34,1 mi | -29,9 mi | |
| 25,2 mi | -45,9 mi | -32,2 mi | |
| 21 mi | -41,8 mi | -27 mi |